Maze Therapeutics (MAZE) stock plunged even as the company posts positive Phase 2 trial data for lead asset MZE829 in APOL1-mediated kidney disease. Read more here.
Maze Therapeutics posts trial data for lead drug (MAZE:NASDAQ)
Maze Therapeutics (MAZE) stock plunged even as the company posts positive Phase 2 trial data for lead asset MZE829 in APOL1-mediated kidney disease. Read more here.